Table 2 Ongoing trials investigating the combination therapy of TKIs and ICIs

Lenvatinib

Nivolumab

I

30

HCC without prior systemic therapy

Active, not recruiting

NCT03418922

Lenvatinib

Nivolumab

II

50

Multinodular, advanced HCC

Recruiting

NCT03841201

Lenvatinib

Pembrolizumab

I

104

HCC

Active, not recruiting

NCT03006926

Lenvatinib

Pembrolizumab

III

750

Advanced HCC

Active, not recruiting

NCT03713593

Regorafenib

Nivolumab

I/II

60

HCC progressing under sorafenib

Recruiting

NCT04170556

Regorafenib

Nivolumab

II

42

Unresectable HCC

Recruiting

NCT04310709

Regorafenib

Nivolumab

III

496

Intermediate-Stage HCC

Not yet recruiting

NCT04777851

Regorafenib

Pembrolizumab

I

57

Advanced liver cancer without prior systemic therapy

Active, not recruiting

NCT03347292

Regorafenib

Pembrolizumab

II

119

Advanced or metastatic HCC after ICIs

Recruiting

NCT04696055

Cabozantinib

Nivolumab

I

15

Locally advanced HCC after definitive resection

Active, not recruiting

NCT03299946

Cabozantinib

Nivolumab

I

18

Advanced Solid Tumors in Patients with HIV Infection

Recruiting

NCT04514484

Cabozantinib

Pembrolizumab

II

29

Liver cancer not eligible for local therapy

Recruiting

NCT04442581

Sorafenib/lenvatinib

Atezolizumab

III

554

Locally advanced or metastatic and/or unresectable HCC participants following prior HCC treatment with atezolizumab and bevacizumab combination

Not yet recruiting

NCT04770896

Bevacizumab

Nivolumab

II

60

Advanced HCC

Recruiting

NCT04393220

Bevacizumab

Atezolizumab

III

662

HCC with high risk of recurrence after surgical resection or ablation

Recruiting

NCT04102098

Bevacizumab

Atezolizumab

III

150

Unresectable HCC without prior systemic treatment

Recruiting

NCT04487067

Bevacizumab

Atezolizumab

III

480

Locally advanced or metastatic HCC without prior systemic treatment

Completed

NCT03434379